The deaf and the dumb: The biology of ErbB-2 and ErbB-3

Experimental Cell Research

Volumn 284, Issue 1, 2003, Pages 54-65

  Citri, Ami ^a   Skaria, Kochupurakkal Bose ^a   Yarden, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE; CELL RECEPTOR; CYCLIN DEPENDENT KINASE; DIMER; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; UNCLASSIFIED DRUG;

BREAST DEVELOPMENT; CANCER CELL; CARCINOMA; CELL CYCLE; CELL LINEAGE; CRYSTAL STRUCTURE; DIMERIZATION; DISSOCIATION; ENDOCYTOSIS; GENE OVEREXPRESSION; HEART DEVELOPMENT; MOLECULAR BIOLOGY; NERVE CELL DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037429779     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4827(02)00101-5     Document Type: Review

References (135)

1. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2:2001;127-137.
2. Guy P.M., Platko J.V., Cantley L.C., Cerione R.A., Carraway K.L. 3rd. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA. 91:1994;8132-8136.
3. Klapper L.N., Glathe S., Vaisman N., Hynes N.E., Andrews G.C., Sela M., Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl. Acad. Sci. USA. 96:1999;4995-5000.
4. Pinkas-Kramarski R., Soussan L., Waterman H., Levkowitz G., Alroy I., Klapper L., Lavi S., Seger R., Ratzkin B.J., Sela M., Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15:1996;2452-2467.
5. Wallasch C., Weiss F.U., Niederfellner G., Jallal B., Issing W., Ullrich A. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14:1995;4267-4275.
6. Baulida J., Kraus M.H., Alimandi M., Di Fiore P.P., Carpenter G. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J. Biol. Chem. 271:1996;5251-5257.
7. Waterman H., Alroy I., Strano S., Seger R., Yarden Y. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J. 18:1999;3348-3358.
8. Burden S., Yarden Y. Neuregulins and their receptors a versatile signaling module in organogenesis and oncogenesis . Neuron. 18:1997;847-855.
9. Coussens L., Yang Feng T.I., Liao Y.C., Chen E., Gray A., McGrath J., Seeburg P.H., Libermann T.A., Schlessinger J., Francke U., Levinson A., Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 230:1985;1132-1139.
10. Prigent S.A., Lemoine N.R., Hughes C.M., Plowman G.D., Selden C., Gullick W.J. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene. 7:1992;1273-1278.
11. Garratt A.N., Britsch S., Birchmeier C. Neuregulin, a factor with many functions in the life of a schwann cell. Bioessays. 22:2000;987-996.
12. Lee K.F., Simon H., Chen H., Bates B., Hung M.C., Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 378:1995;394-398.
13. Gassmann M., Casagranda F., Orioli D., Simon H., Lai C., Klein R., Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 378:1995;390-394.
14. Meyer D., Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 378:1995;386-390.
15. Chan R., Hardy W.R., Laing M.A., Hardy S.E., Muller W.J. The catalytic activity of the ErbB-2 receptor tyrosine kinase is essential for embryonic development. Mol. Cell. Biol. 22:2002;1073-1078.
16. Erickson S.L., O'Shea K.S., Ghaboosi N., Loverro L., Frantz G., Bauer M., Lu L.H., Moore M.W. ErbB3 is required for normal cerebellar and cardiac development a comparison with ErbB2-and heregulin-deficient mice . Development. 124:1997;4999-5011.
17. Riethmacher D., Sonnenberg-Riethmacher E., Brinkmann V., Yamaai T., Lewin G.R., Birchmeier C. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 389:1997;725-730.
18. Crone S.A., Zhao Y.Y., Fan L., Gu Y., Minamisawa S., Liu Y., Peterson K.L., Chen J., Kahn R., Condorelli G., Ross J. Jr., Chien K.R., Lee K.F. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8:2002;459-465.
19. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., Chien K.R., Birchmeier C., Garratt A.N. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA. 99:2002;8880-8885.
20. Adlkofer K., Lai C. Role of neuregulins in glial cell development. Glia. 29:2000;104-111.
21. Britsch S., Li L., Kirchhoff S., Theuring F., Brinkmann V., Birchmeier C., Riethmacher D. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 12:1998;1825-1836.
22. Morris J.K., Lin W., Hauser C., Marchuk Y., Getman D., Lee K.F. Rescue of the cardiac defect in ErbB2 mutant mice reveals essential roles of ErbB2 in peripheral nervous system development. Neuron. 23:1999;273-283.
23. Park S.K., Miller R., Krane I., Vartanian T. The erbB2 gene is required for the development of terminally differentiated spinal cord oligodendrocytes. J. Cell Biol. 154:2001;1245-1258.
24. Grinspan J.B., Marchionni M.A., Reeves M., Coulaloglou M., Scherer S.S. Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve neuregulin receptors and the role of neureguins . J. Neurosci. 16:1996;6107-6118.
25. Levi A.D.O., Bunge R.P., Lofgren J.A., Meima L., Hefti F., Nikolics K., Sliwkowski X.M. The influence of heregulins on human Schwann cell proliferation. J. Neurosci. 15:1995;1329-1340.
26. Davies A.M. Neuronal survival early dependence on Schwann cells . Curr. Biol. 8:1998;R15-R18.
27. Troyer K.L., Lee D.C. Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J. Mammary Gland Biol. Neoplasia. 6:2001;7-21.
28. Yang Y., Spitzer E., Meyer D., Sachs M., Niemann C., Hartmann G., Weidner K.M., Birchmeier C., Birchmeier W. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J. Cell Biol. 131:1995;215-226.
29. Krane I.M., Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene. 12:1996;1781-1788.
30. Jones F.E., Stern D.F. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene. 18:1999;3481-3490.
31. Heldin C.-H., Ostman A. Ligand-induced dimerization of growth factor receptors variations on the theme . Cytokine Growth Factor Rev. 7:1996;33-40.
32. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science. 297:2002;1330-1333.
33. Garrett T.P., McKern N.M., Lou M., Elleman T.C., Adams T.E., Lovrecz G.O., Zhu H.J., Walker F., Frenkel M.J., Hoyne P.A., Jorissen R.N., Nice E.C., Burgess A.W., Ward C.W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell. 110:2002;763-773.
34. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell. 110:2002;775-787.
35. Lax I., Bellot F., Howk R., Ullrich A., Givol D., Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chicken/human receptor molecules. EMBO J. 8:1989;421-427.
36. Summerfield A.E., Hudnall A.K., Lukas T.J., Guyer C.A., Staros J.V. Identification of residues of the epidermal growth factor receptor proximal to residue 45 of bound epidermal growth factor. J. Biol. Chem. 271:1996;19656-19659.
37. Groenen L.C., Nice E.C., Burgess A.W. Structure-function relationships for the EGF/TGF-α family of mitogens. Growth Factors. 11:1994;235-257.
38. Jorissen R.N., Epa V.C., Treutlein H.R., Garrett T.P., Ward C.W., Burgess A.W. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor. Protein Sci. 9:2000;310-324.
39. Greenfield C., Hils I., Waterfield M.D., Federwisch M., Wollmer A., Blundell T.L., McDonald N. EGF binding induces conformational change in the external domain of its receptor. EMBO J. 8:1989;4115-4123.
40. Tzahar E., Pinkas Kramarski R., Moyer J.D., Klapper L.N., Alroy I., Levkowitz G., Shelly M., Henis S., Eisenstein M., Ratzkin B.J., Sela M., Andrews G.C., Yarden Y. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 16:1997;4938-4950.
41. Lemmon M.A., Bu Z., Ladbury J.E., Zhou M., Pinchasi D., Lax I., Engelman D.E., Schlessinger J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 16:1997;281-294.
42. Gadella T.W., Jovin T.M. Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation. J. Cell Biol. 129:1995;1543-1558.
43. Sako Y., Minoghchi S., Yanagida T. Single-molecule imaging of EGFR signalling on the surface of living cells. Nat. Cell Biol. 2:2000;168-172.
44. Berezov A., Chen J., Liu Q., Zhang H.T., Greene M.I., Murali R. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277:2002;28330-28339.
45. Elleman T.C., Domagala T., McKern N.M., Nerrie M., Lonnqvist B., Adams T.E., Lewis J., Lovrecz G.O., Hoyne P.A., Richards K.M., Howlett G.J., Rothacker J., Jorissen R.N., Lou M., Garrett T.P., Burgess A.W., Nice E.C., Ward C.W. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain. Biochemistry. 40:2001;8930-8939.
46. Karunagaran D., Tzahar E., Beerli R.R., Chen X., Graus Porta D., Ratzkin B.J., Seger R., Hynes N.E., Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors implications for breast cancer . EMBO J. 15:1996;254-264.
47. Sliwkowski M.X., Schaefer G., Akita R.W., Lofgren J.A., Fitzpatrick V.D., Nuijens A., Fendly B.M., Cerione R.A., Vandlen R.L., Carraway K.L. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269:1994;14661-14665.
48. Graus Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16:1997;1647-1655.
49. Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., Ratzkin B.J., Yarden Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16:1996;5276-5287.
50. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1987;178-182.
51. Hudziak R.M., Schlessinger J., Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA. 84:1987;7159-7163.
52. Bargmann C.I., Hung M.C., Weinberg R.A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 45:1986;649-657.
53. Cohen B.D., Kiener P.A., Green J.M., Foy L., Fell H.P., Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J. Biol. Chem. 271:1996;30897-30903.
54. Kokai Y., Myers J.N., Wada T., Brown V.I., LeVea C.M., Davis J.G., Dobashi K., Greene M.I. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell. 58:1989;287-292.
55. Reed J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17:1999;2941-2953.
56. Riese D.J. 2nd, van Raaij T.M., Plowman G.D., Andrews G.C., Stern D.F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15:1995;5770-5776.
57. Zhang K., Sun J., Liu N., Wen D., Chang D., Thomason A., Yoshinaga S.K. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271:1996;3884-3890.
58. Peles E., Ben-Levy R., Tzahar E., Liu N., Wen D., Yarden Y. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12:1993;961-971.
59. neu protein and EGF receptor modulates EGF receptor function. Cell. 61:1990;1339-1347.
60. Alimandi M., Wang L.M., Bottaro D., Lee C.C., Kuo A., Frankel M., Fedi P., Tang C., Lippman M., Pierce J.H. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors. EMBO J. 16:1997;5608-5617.
61. Pinkas-Kramarski R., Lenferink A.E., Bacus S.S., Lyass L., van de Poll M.L., Klapper L.N., Tzahar E., Sela M., van Zoelen E.J., Yarden Y. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene. 16:1998;1249-1258.
62. Wang L.M., Kuo A., Alimandi M., Very M.C., Lee C.C., Kapoor V., Ellmore N., Chen X.H., Pierce J.H. ErbB-2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB-4. Proc. Natl. Acad. Sci. USA. 95:1998;6809-6814.
63. Waterman H., Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 490:2001;142-152.
64. Levkowitz G., Waterman H., Zamir E., Kam Z., Oved S., Langdon W.Y., Beguinot L., Geiger B., Yarden Y. c-Cb1/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12:1998;3663-3674.
65. Levkowitz G., Waterman H., Ettenberg S.A., Katz M., Tsygankov A.Y., Alroy I., Lavi S., Iwai K., Reiss Y., Ciechanover A., Lipkowitz S., Yarden Y. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cb1/Sli-1. Mol. Cell. 4:1999;1029-1040.
66. Lill N.L., Douillard P., Awwad R.A., Ota S.M.L., Lupher Miyake S. Jr., Meissner-Lula N., Hsu V.W., Band H. The evolutionarily conserved N-terminal region of Cbl is sufficient to enhance down-regulation of the epidermal growth factor receptor. J. Biol. Chem. 275:2000;367-377.
67. Waterman H., Levkowitz G., Alroy I., Yarden Y. The RING finger of c-Cb1 mediates desensitization of the epidermal growth factor receptor. J. Biol. Chem. 274:1999;22151-22154.
68. Yokouchi M., Kondo T., Houghton A., Bartkiewicz M., Horne W.C., Zhang H., Yoshimura A., Baron R. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbeH7. J. Biol. Chem. 274:1999;31707-31712.
69. Levkowitz G., Klapper L.N., Tzahar E., Freywald A., Sela M., Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene. 12:1996;1117-1125.
70. Muthuswamy S.K., Gilman M., Brugge J.S. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol. Cell. Biol. 19:1999;6845-6857.
71. Baulida J., Carpenter G. Heregulin degradation in the absence of rapid receptor-mediated internalization. Exp. Cell. Res. 232:1997;167-172.
72. Waterman H., Sabanai I., Geiger B., Yarden Y. Alternative intracellular routing of ErbB receptors may determine signaling potency. J. Biol. Chem. 273:1998;13819-13827.
73. Lenferink A.E., Pinkas Kramarski R., van de Poll M.L., van Vugt M.J., Klapper L.N., Tzahar E., Waterman H., Sela M., van Zoelen E.J., Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17:1998;3385-3397.
74. Sorkin A., Di Fiore P.P., Carpenter G. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. Oncogene. 8:1993;3021-3028.
75. Worthylake R., Opresko L.K., Wiley H.S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274:1999;8865-8874.
76. Ben-Levy R., Paterson H.F., Marshall C.J., Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 13:1994;3302-3311.
77. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13:1994;2831-2841.
78. Peles E., Lamprecht R., Ben-Levy R., Tzahar E., Yarden Y. Regulated coupling of the Neu receptor to phosphatidylinositol 3′-kinase and its release by oncogenic activation. J. Biol. Chem. 267:1992;12266-12274.
79. Fazioli F., Kim U.H., Rhee S.G., Molloy C.J., Segatto O., Di Fiore P.P. The erbB-2 mitogenic signaling pathway tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency . Mol. Cell. Biol. 11:1991;2040-2048.
80. Peles E., Levy R.B., Or E., Ullrich A., Yarden Y. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. EMBO J. 10:1991;2077-2086.
81. Liu J., Kern J.A. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am. J. Respir. Cell. Mol. Biol. 27:2002;306-313.
82. Fedi P., Pierce J.H., di Fiore P.P., Kraus M.H. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C gamma or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol. Cell. Biol. 14:1994;492-500.
83. Bar-Sagi D., Hall A. Ras and Rho GTPases a family reunion . Cell. 103:2000;227-238.
84. Waterman H., Katz M., Rubin C., Shtiegman K., Lavi S., Elson A., Jovin T., Yarden Y. A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J. 21:2002;303-313.
85. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr. Opin. Gen. Dev. 4:1994;82-89.
86. Toker A., Newton A.C. Cellular signaling pivoting around PDK-1 . Cell. 103:2000;185-188.
87. Blume-Jensen P., Hunter T. Oncogenic kinase signaling. Nature. 411:2001;355-365.
88. Meier R., Hemmings B.A. Regulation of protein kinase B. J. Recept. Signal Transduct. Res. 19:1999;121-128.
89. Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 296:2002;1655-1657.
90. Karin M., Hunter T. Transcriptional control by protein phosphorylation signal transmission from the cell surface to the nucleus . Curr. Biol. 5:1995;747-757.
91. Hunter T. Signaling - 2000 and beyond. Cell. 100:2000;113-127.
92. Bourguignon L.Y., Zhu H., Chu A., Iida N., Zhang L., Hung M.C. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J. Biol. Chem. 272:1997;27913-27918.
93. Sherman L.S., Rizvi T.A., Karyala S., Ratner N. CD44 enhances neuregulin signaling by Schwann cells. J. Cell. Biol. 150:2000;1071-1084.
94. Jepson S., Komatsu M., Haq B., Arango M.E., Huang D., Carraway C.A., Carraway K.L. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene. 21:2002;7524-7532.
95. Harari D., Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 19:2000;6102-6114.
96. Lenferink A.E., Busse D., Flanagan W.M., Yakes F.M., Arteaga C.L. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. Cancer Res. 61:2001;6583-6591.
97. Lee R.J., Albanese C., Fu M., D'Amico M., Lin B., Watanabe G., Haines G.K. 3rd, Siegel P.M., Hung M.C., Yarden Y., Horowitz J.M., Muller W.J., Pestell R.G. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20:2000;672-683.
98. Wulf G.M., Ryo A., Wulf G.G., Lee S.W., Niu T., Petkova V., Lu K.P. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 20:2001;3459-3472.
99. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12:1998;3499-3511.
100. Muraoka R.S., Lenferink A.E., Law B., Hamilton E., Brantley D.M., Roebuck L.R., Arteaga C.L. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 22:2002;2204-2219.
101. Neve R.M., Sutterluty H., Pullen N., Lane H.A., Daly J.M., Krek W., Hynes N.E. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 19:2000;1647-1656.
102. Fiorini M., Ballaro C., Sala G., Falcone G., Alema S., Segatto O. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene. 21:2002;6530-6539.
103. Fiorentino L., Pertica C., Fiorini M., Talora C., Crescenzi M., Castellani L., Alema S., Benedetti P., Segatto O. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell. Biol. 20:2000;7735-7750.
104. Azios N.G., Romero F.J., Denton M.C., Doherty J.K., Clinton G.M. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene. 20:2001;5199-5209.
105. Lee H., Akita R.W., Sliwkowski M.X., Maihle N.J. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 61:2001;4467-4473.
106. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., Patterson C., Neckers L., Fry D.W., Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases implications for cancer therapy . EMBO. J. 21:2002;2407-2417.
107. Xu W., Marcu M., Yuan X., Mimnaugh E., Patterson C., Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. USA. 99:2002;12847-12852.
108. Rosenthal A., Lindquist P.B., Bringman T.S., Goeddel D.V., Derynck R. Expression in rat fibroblasts of a human transforming growth factor-alpha cDNA results in transformation. Cell. 46:1986;301-309.
109. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19:1995;183-232.
110. Alimandi M., Romano A., Curia M.C., Muraro R., Fedi P., Aaronson S.A., Di Fiore P.P., Kraus M.H. Cooperative signaling of ErbB-3 and ErbB-2 in neoplastic transformation of human mammary carcinoma cells. Oncogene. 15:1995;1813-1821.
111. Lonardo F., Di Marco E., King C.R., Pierce J.H., Segatto O., Aaronson S.A.D.i, Fiore P.P. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol. 2:1995;992-1003.
112. Yarden Y. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proc. Natl. Acad. Sci. USA. 87:1990;2569-2573.
113. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science. 235:1987;177-182.
114. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., Press M.F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:1989;707-712.
115. Allred D.C., Clark G.M., Molina R., Tandon A.K., Schnitt S.J., Gilchrist K.W., Osborne C.K., Tormey D.C., McGuire W.L. Overexpression of HER-2/Neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum. Pathol. 23:1992;974-979.
116. Gullick W.J., Srinivasan R. The type 1 growth factor receptor family new ligands and receptors and their role in breast cancer . Breast Cancer Res. Treat. 52:1998;43-53.
117. Hynes N.E., Stern D.F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem. Biophys. Acta. 1198:1994;165-184.
118. Klapper L.N., Kirschbaum M.H., Sela M., Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 77:2000;25-79.
119. Suo Z., Risberg B., Kalsson M.G., Willman K., Tierens A., Skovlund E., Nesland J.M. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J. Pathol. 196:2002;17-25.
120. Gilbertson R.J., Perry R.H., Kelly P.J., Pearson A.D., Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57:1997;3272-3280.
121. Bodey B., Bodey B. Jr., Groger A.M., Luck J.V., Siegel S.E., Taylor C.R., Kaiser H.E. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res. 17:1997;1319-1330.
122. N.R. Lemoine, D.M. Barnes, D.P. Hollywood, C.M. Hughes, P. Smith, E. Dublin, S.A. Prigent, W.J. Gullick, H.C. Hurst, Expression of the ERBB3 gene product in breast cancer, Br. J. Cancer 66 (1992) 1116-1121.
123. Maurer C.A., Friess H., Kretschmann B., Zimmermann A., Stauffer A., Baer H.U., Kore M., Buchler M.W. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum. Pathol. 29:1998;771-777.
124. Xia W., Lau Y.K., Zhang H.Z., Xiao F.Y., Johnston D.A., Liu A.R., Li L., Katz R.L., Hung M.C. Combination of EGFR, HER-2/neu, and HER- 3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin. Cancer Res. 5:1999;4164-4174.
125. Yi E.S., Harclerode D., Gondo M., Stephenson M., Brown R.W., Younes M., Cagle P.T. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod. Pathol. 10:1997;142-148.
126. Simpson B.J., Weatherill J., Miller E.P., Lessells A.M., Langdon S.P., Miller W.R. c-erbB-3 protein expression in ovarian tumours. Br. J. Cancer. 71:1995;758-762.
127. Ito Y., Takeda T., Sakon M., Tsujimoto M., Higashiyama S., Noda K., Miyoshi E., Monden M., Matsuura N. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br. J. Cancer. 84:2001;1377-1383.
128. Chow N.H., Chan S.H., Tzai T.S., Ho C.L., Liu H.S. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7:2001;1957-1962.
129. Derynck R., Goeddel D.V., Ullrich A., Gutterman J.U., Williams R.D., Bringman T.S., Berger W.H. Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal-growth-factor-receptor by human tumors. Cancer Res. 47:1987;707-712.
130. deFazio A., Chiew Y.E., Sini R.L., Janes P.W., Sutherland R.L. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int. J. Cancer. 87:2000;487-498.
131. Friess H., Berberat P., Schilling M., Kunz J., Kore M., Buchler M.W. Pancreatic cancer the potential clinical relevance of alterations in growth factors and their receptors . J. Mol. Med. 74:1996;35-42.
132. Carpenter G. Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways. J. Cell Biol. 146:1999;697-702.
133. Schweitzer R., Howes R., Smith R., Shilo B.-Z., Freeman M. Inhibition of Drosophila EGF receptor activation by the secreted Argos protein. Nature. 376:1995;699-702.
134. Nagy P., Vereb G., Sebestyen Z., Horvath G., Lockett S.J., Damjanovich S., Park J.W., Jovin T.M., Szollosi J. Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J. Cell Sci. 115:2002;4251-4262.
135. Tzahar E., Moyer J.D., Waterman H., Barbacci E.G., Bao J., Levkowitz G., Shelly M., Strano S., Pinkas-Kramarski R., Pierce J.H., Andrews G.C., Yarden Y. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J. 17:1998;5948-5963.